Navigation Links
Blood sugar's manufacture limited by building blocks' supply

Researchers have discovered a factor that controls blood sugar's manufacture in a novel way: by limiting the supply of its building blocks. The findings are reported in the April issue of the journal Cell Metabolism, published by Cell Press.

The study found that mice deficient for KLF15, a member of the so-called Krüppel-like family of transcription factors, become severely lacking in the blood sugar glucose—a primary energy source for the body and the sole source for the brain—after a period of overnight fasting. The researchers traced that deficiency back to an inability to produce new glucose in the liver, a process known as gluconeogenesis, due to a defect in the processing of amino acids. Amino acids are the main ingredients of proteins and the source of a key substrate in blood sugar's production.

"Gluconeogenesis is a complicated process," said Mukesh K. Jain of Case Western Reserve University. "It fundamentally requires two big things: the building blocks and the [glucose-building] enzymes that make it all happen. A lot of previous work has focused on the enzymes."

"We've found the first defect [in glucose production] due to a loss of substrate," added Susan Gray of Brigham and Women's Hospital.

During fasting, the supply of glucose derived from food dries up, Gray explained. In response, the body first breaks down liver glycogen, the principal storage form of glucose. However, the body "goes through those stores overnight," she said.

Once the reserves are depleted, the body must rely on the synthesis of new glucose, primarily in the liver, to prevent a life-threatening shortage, a condition known as hypoglycemia. The de novo synthesis of glucose depends on the availability of a substrate molecule that comes from an amino acid.

The researchers found that mice with a targeted deletion of KLF15 display severe hypoglycemia after an overnight fast. They further found evidence that defective amino acid brea
'"/>

Source:Cell Press


Page: 1 2

Related biology news :

1. Placenta Is A Rich Source Of Blood Stem Cells
2. Infants With Rare Genetic Disease Saved by Cord Blood Stem Cells
3. White Blood Cell Waste Disposal System Plays Critical Regulatory Role
4. Mystery Blood Vessel Disorder Implicated In Mini Strokes
5. Infants with Rare Genetic Disease Saved By Cord Blood Stem Cells
6. Young Blood Revives Aging Muscles, Stanford Researchers Find
7. Stem Cells to Solve the Blood Shortage Problem?
8. Blood flow in brain takes a twist, affecting views of Alzheimers
9. Blood test predicts success of quitting smoking using the nicotine patch
10. Blood-compatible nanoscale materials possible using heparin
11. Blood transfusion-transmitted infections: A global perspective
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Blood sugar manufacture limited building blocks supply

(Date:8/6/2015)... , Aug. 6, 2015 Synaptics Inc. ... human interface solutions, today announced collaboration with Microsoft ... Windows 10. Microsoft leveraged Synaptics, deep expertise in ... system. Through stringent testing, Synaptics, ... certified with Microsoft,s Precision TouchPad (PTP) specification empowering ...
(Date:8/5/2015)... New York , August 5, 2015 ... market report titled "Facial Recognition Market - Global Industry ... 2022", the global market for facial recognition is forecast ... is driven by increased demand for surveillance systems by ... the rising number of crimes and terrorist activities across ...
(Date:8/4/2015)... DUBLIN , Aug. 04, 2015 /PRNewswire/ ... ( http://www.researchandmarkets.com/research/nvh7k2/digital_forensics ) has announced the addition ... Component (Hardware, Software, and Service), Sub-Segment (Computer ... Cloud Forensics), Tool Types, Service, Vertical and ... report to their offering. By ...
Breaking Biology News(10 mins):Synaptics Chosen for Human Interface Co-Development on Windows 10 2Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 2Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 3Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 4Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 5Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 6Digital Forensics Market - The Market Represents a Compound Annual Growth Rate (CAGR) of 11.3% From 2015 to 2020 2
... University and the University of Missouri are developing a ... useful byproducts at a cost of less than a ... the technological aspects of the project, the researchers are ... developing countries, since many areas with the greatest sanitation ...
... flu strain that emerged in China earlier this year has ... be reassured by this apparent lull in infections. The virus ... of a pathogen that may yet lead to a pandemic, ... and Infectious Diseases. David Morens, Jeffery Taubenberger, and Anthony Fauci, ...
... Boston As the population gets older, and the baby ... assume that the number of trips to the emergency department ... Brigham and Women,s Hospital (BWH), which shows that population aging ... to increase between now and 2050. However, visits will become ...
Cached Biology News:Pressure cooker on steroids treats human waste 2Pressure cooker on steroids treats human waste 3H7N9 influenza: History of similar viruses gives cause for concern 2H7N9 influenza: History of similar viruses gives cause for concern 3The aging population and emergency departments 2
(Date:8/26/2015)... , Aug. 26, 2015 /PRNewswire/ - iCo Therapeutics ... today reported financial results for the quarter ended ... expressed in Canadian dollars and presented under International ... pre-clinical activities with respect to our Oral Amp ... a contract manufacturer," said Andrew Rae , ...
(Date:8/26/2015)... ... August 26, 2015 , ... ... investment in the development and manufacture of highly valued cardiac markers used in ... team's extensive expertise with protein chemistry has led to the development and commercialization ...
(Date:8/26/2015)... FRANCISCO , Aug. 26, 2015  Platform ... that it has received a $1.5M Phase II ... (NIH) to further develop its therapeutic agent to ... clinical need in end stage renal disease (ESRD) ... the National Institute of Diabetes and Digestive and ...
(Date:8/26/2015)... BEIJING , August 26, 2015 ... Acheivements  DiaCardio wins 1 st place  ... competition, led in Israel by venture capital ... from countries including the US, China , ... Latin America .  Impressive achievement for the ...
Breaking Biology Technology:iCo Therapeutics Announces Second Quarter 2015 Financial Results 2iCo Therapeutics Announces Second Quarter 2015 Financial Results 3Lee Biosolutions Announces Increased Investment in the Development and Manufacturing of Biomarkers Used in Early Detection Of Heart Disease 2Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 2Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 3Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 2Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 3Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 4Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 5Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 6
... Inc. today announced the,scheduled presentation of data from ... long-acting human growth hormone (hGH) analogue developed in,collaboration ... meeting in Rio de Janeiro. Andrew R. Hoffman, ... Affairs at Stanford University,will present the clinical results ...
... Incorporated (Nasdaq:,VICL) today reported financial results for the quarter ended ... $0.8 million, compared,with revenues of $0.4 million for the third ... 2008 was $9.8 million or $0.24 per share, compared,with $9.2 ... 2007., Revenues for the first nine months of 2008 ...
... - Oncolytics Biotech Inc.,(TSX:ONC, NASDAQ:ONCY) ("Oncolytics" or ... the three and nine-month periods ended September ... Oncolytics made a decision in early November ... using the combination of REOLYSIN(R) with,paclitaxel/carboplatin in ...
Cached Biology Technology:Ambrx to Present Phase I/II Clinical Data for Optimized, Long Acting Human Growth Hormone Analogue 2Vical Reports Third Quarter 2008 Financial Results and Continued Progress in Product Development Programs 2Vical Reports Third Quarter 2008 Financial Results and Continued Progress in Product Development Programs 3Vical Reports Third Quarter 2008 Financial Results and Continued Progress in Product Development Programs 4Vical Reports Third Quarter 2008 Financial Results and Continued Progress in Product Development Programs 5Vical Reports Third Quarter 2008 Financial Results and Continued Progress in Product Development Programs 6Oncolytics Biotech Inc. Announces 2008 Third Quarter Results 2Oncolytics Biotech Inc. Announces 2008 Third Quarter Results 3Oncolytics Biotech Inc. Announces 2008 Third Quarter Results 4Oncolytics Biotech Inc. Announces 2008 Third Quarter Results 5Oncolytics Biotech Inc. Announces 2008 Third Quarter Results 6Oncolytics Biotech Inc. Announces 2008 Third Quarter Results 7Oncolytics Biotech Inc. Announces 2008 Third Quarter Results 8Oncolytics Biotech Inc. Announces 2008 Third Quarter Results 9
... expression vectors, we in-troduced a new concept, namely ... tran-scriptional level at the T7 phage promoter, and ... the plasmid copy number, The main advantage of ... practically all of the outstanding features of the ...
Mouse monoclonal [34B12] to Nop5p + Nop58p - Nucleolar Marker ( Abpromise for all tested applications)....
... the ultimate tool for investigating dynamic events ... previously have been limited at wavelengths longer ... not transmit in the deep UV. HORIBA ... introduces a filter-based confocal system (the DynaMic) ...
... G bind specifically to Fc regions of ... G conjugates are commonly used as affinity ... subtypes from serum, hybridoma ascites fluids, tissue ... reagents are also commonly used to capture ...
Biology Products: